CGM: SENS/Ascensia Reinitiate EU Eversense XL Commercial Activities; Nemaura Appoints Jay Warner as Head of US Commercial Operations
Two diabetes-related news items have been observed: Senseonics announced its partner, Ascensia, has reinitiated EU commercial activities for the Eversense XL implantable CGM system; and Nemaura Medical announced the appointment of Jay Warner as Head of US Commercial Operations. Below, FENIX provides highlights and insights for the respective news items, including the curious mention of Livongo in the Nemaura press release.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.